Complement-mediated kidney diseases (CMKDs) are a complex group of disorders impacting nearly all aspects of patients’ lives; however, the treatment armamentarium is rapidly evolving with the development of several new and emerging targeted therapies. Up-to-date knowledge of the evidence for these novel complement-directed therapies is needed to facilitate timely access, optimized medication use, improved outcomes, and efficient resource utilization by care providers and managed care professionals. Tune in to this on-demand video to hear as leading experts discuss the latest treatment advances in CMKDs and implications for managed care decision-making. The faculty will explore the unmet needs of patients with CMKDs, review the latest clinical data, and discuss strategies for integrating new and emerging therapies into practice as they become available.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/emerging-clinical-evidence-novel-cmkd-therapies-implications-managed-care
- Start Date: 2024-11-26 06:00:00
- End Date: 2024-11-26 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 44916.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all